Date issuedProductSafety information
1/16/2020 Olmepress (Olmesartan)

Restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing Olmepress (Olmesartan).CLICK HERE​

12/12/2019 Kyprolis® ( Carfilzomib)

Kyprolis (carfilzomib) – New Safety Information: Risk of Progressive Multifocal Leukoencephalopathy (PML) and Hepatitis B Virus (HBV) Reactivation.CLICK HERE

12/8/2019 Esbriet® (Pirfenidone)

Important Safety Update on ESBRIET® (pirfenidone) and Drug-Induced Liver Injury (DILI).CLICK HERE

11/14/2019 FEGONA®

FEGONA (fingolimod) – New contraindication in pregnant women and in women of childbearing potential not using effective contraception ​. CLICK HERE​​​​​

10/21/2019 Zofran®

Direct Healthcare Professional Communication on the risk of birth defects from the recently published epidemiological studies for Zofran® (Ondansetron)  . CLICK HERE​​​​​​

9/19/2019 Methotrexate "Ebewe”

​Recommendations to avoid potentially fatal dosing errors when using methotrexate “METHOTREXATE "EBEWE “ for autoimmune diseases ​CLICK HERE​​​​​

9/11/2019 Roaccutne

Roaccutne (isotretinoin): An update on neuropsychiatric disorders.CLICK HERE​​​​

8/26/2019 soliqua (lixisenatide /insuline glargin) soliqua

(lixisenatide /insuline glargin):  Important information on dosing.CLICK HERE​​​

8/26/2019 Advaquin ( levofloxacin)

Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection.CLICK HERE​​​

8/8/2019 Gilenya (fingolimod)

Gilenya (fingolimod)): New contraindication in pregnant women and in women of childbearing potential not using effective contraception.CLICK HERE​​​​

12345...الأخيرة